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ABSTRACT
Background The global COVID-19 pandemic has 
impacted on the mental health of individuals, particularly 
those with chronic illnesses. We aimed to quantify 
stress, anxiety and depression among individuals with 
Inflammatory bowel disease (IBD) in Australia during the 
pandemic.
Methods An electronic survey was made available to IBD 
patients Australia- wide from 17 June to 12 July 2020. 
Respondents with an underlying diagnosis of IBD and over 
18 years of age were included. A validated questionnaire 
(Depression, Anxiety, Stress Score-21, DASS21) was 
used to assess depression, anxiety and stress. Data on 
potential predictors of depression, anxiety and stress were 
collected.
Results 352 participated in the survey across Australia. 
60.5% of respondents fulfilled DASS criteria for at least 
moderate depression, anxiety or stress. 45% reported a 
pre- existing diagnosis of depression and/or anxiety. Over 
2/3 of these respondents reported worsening of their pre- 
existing depression/anxiety due to the current pandemic. 
Of those without a pre- existing diagnosis of anxiety or 
depression, high rates of at least moderate to severe 
depression (34.9%), anxiety (32.0%) and stress (29.7%) 
were noted. Younger age (OR 0.96, 95% CI 0.94 to 0.98, 
p<0.001), lack of access to an IBD nurse (OR 1.81, 95% CI 
1.03 to 3.19, p=0.04) and lack of education on reducing 
infection risk (OR 1.99, 95% CI 1.13 to 3.50, p=0.017) 
were associated with significant stress, anxiety and/or 
depression.
Conclusion High prevalence of undiagnosed depression, 
anxiety and stress was identified among respondents. 
Improved access to IBD nurse support and greater 
attention to education are modifiable factors that may 
reduce depression, anxiety and/or stress among patients 
with IBD during the pandemic.
INTRODUCTION
The COVID-19 outbreak has caused fears of 
morbidity and mortality from potential infec-
tion, and the impact of social distancing on 
financial well- being, relationships and mental 
health worldwide. High rates of depression, 
anxiety and stress have been documented in 
countries with high rates of COVID-19, such 
as China and Italy.1 2 Factors such as female 
gender, negative affect, detachment and 
having an infected acquaintance have been 
found to be associated with increased levels 
of depression, anxiety and/or stress.
Inflammatory bowel disease (IBD) is a 
chronic autoinflammatory condition that 
Summary box
What is already known about this subject?
 ► People with inflammatory bowel disease (IBD) have 
higher background rates of depression and anxiety 
than the general population, and may be more sus-
ceptible to the negative mental health impact of the 
COVID-19 pandemic.
 ► There are no prior Western country studies that have 
quantified depression and anxiety rates among pa-
tients with IBD during the pandemic.
What are the new findings?
 ► High rates of depression, anxiety and stress were 
noted in respondents. Even those without a prior di-
agnosis of depression or anxiety had high rates of 
significant depression (34.9%), anxiety (32.0%) and 
stress (29.7%).
 ► Predictors for at least moderate depression, anxiety 
or stress included younger age, symptomatic dis-
ease, lack of access to an IBD nurse, lack of ad-
vice from medical practitioner regarding reducing 
COVID-19 infection and perceived increased sus-
ceptibility to COVID-19 compared with the general 
population.
How might it impact on clinical practice in the 
foreseeable future?
 ► This study highlights the need to support the men-
tal health of patients with IBD during the global 
pandemic.
 ► Improved access to subspecialty nurses and medi-
cal practitioner advice on reducing infection risk are 
two modifiable factors that may reduce depression, 
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affects the gastrointestinal tract. Peak onset is typically 
in young adults, however, IBD affects individuals from 
the entire age spectrum. IBD is well known to have a 
substantial impact on quality of life: individuals with IBD 
have comparatively higher rates of anxiety and depres-
sion than the general population.3 In addition, immuno-
suppressive medications may heighten individual fears 
of infection during the present COVID-19 pandemic. 
Individuals with IBD may hence be more susceptible 
to the negative mental health impact of the COVID-19 
pandemic compared with the general population.
To date, there has been scarce data on the impact of 
the COVID-19 pandemic on the mental health of people 
living with IBD. The aim of our study was to assess the 
impact of the COVID-19 pandemic on the mental health 
of individuals with IBD living in Australia. Australian 
states introduced social distancing rules in March 2020 
to combat the spread of COVID-19. In addition, we seek 
to find factors that are associated with increased depres-
sion, anxiety and stress, to allow for future interventional 
studies.
METHODS
Study design and study population
We conducted a cross- sectional survey of individuals living 
with IBD in Australia. The survey content was developed 
by a group consisting of three gastroenterologists, a clin-
ical psychologist, an IBD clinical nurse consultant and a 
gastroenterology trainee. The final content was approved 
by consensus. The study was conducted between 17 June 
and 12 July 2020. The electronic survey was uploaded on 
an online platform (Survey Monkey) and was advertised 
using the social media platforms of Crohn’s and Colitis 
Australia and the Western Sydney Local Health District. 
Efforts were made to advertise the survey widely. Poten-
tial participants could access the survey via an online link.
A validated questionnaire (Depression, Anxiety, Stress 
Score-21, DASS21) was used to assess depression, anxiety 
and stress in respondents.4 The DASS-21 is a self- report 
questionnaire consisting of 21 items with 7 items per 
subscale domain: depression, anxiety and stress. Respon-
dents score each item from 0 to 3, and item scores are 
added together and multiplied by 2 for each domain to 
generate three subscale scores. Depression subscale scores 
corresponds to normal population (0–9), mild (10–13), 
moderate (14–20) and severe symptoms (21–27). Anxiety 
subscale scores correspond to normal population (0–7) 
mild, (8–9) moderate (10–14) and severe symptoms 
(15–19). Similarly, stress subscale scores corresponded 
to normal population (0–14), mild (15–18), moderate 
(19–25) or severe symptoms (26-33). Significant depres-
sion, anxiety and/or stress in our study was defined as at 
least moderate DASS21 subscores for depression, anxiety 
and/or stress. We also collected data on demographics, 
IBD phenotype and disease activity, other medical history 
and potential predictors of depression, anxiety and stress 
(see online supplemental table 1 for full questionnaire).
Study participants
All respondents living in Australia, with an underlying 
diagnosis of IBD, and over 18 years of age were included. 
IP address restrictions meant each participant could fill 
out the survey only once. The survey was anonymous, and 
no personal data were collected at any stage.
Patient and public involvement
A survey draft was trialled on 10 patients with IBD who 
attend the IBD service at Blacktown hospital. Qualitative 
feedback was obtained on time taken to complete the 
survey, its content and its clarity. The survey was edited 
based on this.
Statistical analysis
Descriptive statistics were used to analyse response to 
questions. Univariate and multivariate logistic regres-
sion analyses were used to determine if associations exist 
between respondent characteristics and stress, depres-
sion and anxiety. Results were expressed as ORs with 
95% CI. A p<0.05 was considered as statistically signifi-
cant. Statistical analyses were conducted using IBM SPSS 
statistics V.26.
Completion of the questionnaire was considered as 
implied consent for participation in the study.
RESULTS
There were 352 respondents to the survey (table 1). The 
mean age of respondents was 40 years (SD 14 years), and 
majority were female (79%). Most respondents were from 
New South Wales (NSW) (54%) and Victoria (23%). 
University- level education was completed by 48% of the 
respondents and 44% were in full time employment. A 
diagnosis of Crohn’s disease (CD) was reported by 59%, 
ulcerative colitis by 36% and indeterminate colitis by 
5%. Thirty- nine per cent of CD respondents reported 
perianal involvement. Severe, moderately severe and 
mild symptoms were reported by 14%, 20% and 43% of 
respondents, respectively, while 23% reported to be in 
clinical remission without symptoms.
Private gastroenterologists managed 50% of patients 
and 26% were managed in dedicated public IBD clinics 
(table 2). An IBD nurse was accessible by 46% of respon-
dents. Current systemic steroids use was reported by 11% 
of respondents, with 45% reported being on an immuno-
modulator and 55% on a biologic. Only 1.8% and 3.4% 
of patients stopped their medications during COVID-19 
pandemic on their own accord and based on advice by a 
health professional, respectively. Access to telehealth was 
available to majority of the respondents (67.5%). COVID-
19- specific health education was only received by 53% of 
respondents, with 97.2% of those who receive education 
agreeing that the information provided was useful.
More than 90% of respondents had at least some 
concerns about contracting COVID-19, while 74.7% 
either strongly agreed or agreed that they were more 
susceptible to contracting the infection compared with 
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Gender (n=351) Male 20.5
Female 78.8
Other 0.6
Age (n=352)   Median 38
(IQR 29–49)







Education (n=353) Primary or secondary 
school
9.1


















Peri- anal Crohn’s 
(n=201)
Yes 39.3
Age at IBD diagnosis   Median 26
(IQR 20–34)
Current Clinical 

















Nil other medical 
condition
71.8
COPD, Chronic obstructive pulmonary disease; IBD, inflammatory 
bowel disease.
Table 2 IBD Medication and management, questionnaire 
responses
Question (no of 
responders) Responses Frequency (%)
Current medications 































Frequently missed a 
dose
3.4
IBD follow- up 
(n=334)
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of depression and/or anxiety was reported by 45% of 
respondents. More than 2/3 of these patients reported 
worsening of their diagnosis due to the psychological 
impact of the current pandemic (table 3). 60.5% of 
respondents fulfilled DASS criteria for at least moderate 
depression, anxiety and/or stress (figure 1). Of those 
without a pre- existing diagnosis of anxiety or depres-
sion, 34.9% met criteria for at least moderate depres-
sion, 32.0% met criteria for at least moderate anxiety and 
29.7% met criteria for at least moderate stress.
Univariate and multivariate analysis was performed 
to assess predictors of depression, anxiety and/or stress 
using baseline characteristics (table 4). Statistically 
significant predictors for at least moderate depression, 
anxiety or stress on multivariate analysis included: 
younger age, lack of immunomodulator use, symptom 
status, lack of access to IBD nurse, lack of advice from 
medical practitioner regarding reducing COVID-19 
infection risk and perceived increased susceptibility 
to COVID-19 compared with general population With 
regards to current symptom status, moderate and severe 
disease activity was associated with increased depres-
sion, anxiety and/or stress. There was no statistically 
significant difference between individuals with mild 
symptoms compared with those who were asymp-
tomatic. Current biological therapy or combination 
therapy (biological and immunomodulator) were not 
associated with significant depression, anxiety and/or 
stress. However, immunomodulator monotherapy was 
associated with lower depression and anxiety.
There was no significant association with gender, educa-
tion level, employment status, IBD diagnosis, current 
treatment with steroids, biologics, IBD medication knowl-
edge, IBD medication compliance, gastroenterology 
Question (no of 
responders) Responses Frequency (%)
Place of 
presentation in 
event of significant 














event of significant 













medications due to 
COVID-19 pandemic 
(n=326)
Yes, on own accord 1.8




Advised by a health 
provider to stop IBD 











ASA, Aminosalicylic acid; GP, general practitioner; IBD, 
inflammatory bowel disease; TNF, tumour necrosis factor.
Table 2 Continued Table 3 Psychological impact of COVID-19 pandemic, 
questionnaire responses
Question (no of 
responders) Responses Frequency (%)
Level of concern 
regarding contracting 
COVID-19 (n=328)
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COVID-19 coverage 
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phone- based review access and exposure to COVID-19 
information on news and social media.
DISCUSSION
Fears of infection and the necessities of social 
distancing have taken a toll on the mental health of the 
general population during the COVID-19 pandemic.5 6 
People suffering from chronic illness have been found 
to experience greater distress than the general popu-
lation during the COVID-19 pandemic.7 Higher rates 
of pre- existing mental health problems and perceived 
increased susceptibility to infection may contribute to 
this. Patients with IBD can be considered in this cate-
gory. Although several publications have addressed the 
practical side of managing patients with IBD during 
the COVID-19 pandemic, the impact of the COVID-19 
pandemic on the mental health of patients with IBD 
is less well understood. Two cross- sectional survey 
studies have not demonstrated a significant impact 
of the COVID-19 pandemic or social distancing on 
the quality of life among adult or paediatric patients 
with IBD.8 9 A cross- sectional survey study of patients 
with IBD from Saudi Arabia demonstrated that almost 
half of respondents had clinical anxiety, however, no 
respondent reported scores consistent with depression 
during the pandemic.10 Particularly, this lack of depres-
sion in an IBD population is at odds with other findings 
and may be due to social or cultural differences or a 
measurement bias due the methodology employed.11 
Hence, we advise caution in extrapolating these results 
to a Western IBD population. Further complicating 
this matter are differences in the local public health 
response in terms of social distancing, the local avail-
ability of personal protective equipment and the local 
dynamics of COVID-19 infections and mortality.
Overall, our study population had relatively high rates 
of depression, anxiety and stress. These were higher 
than reported rates in the general Australian popula-
tion (depression 12- month prevalence 4.1%, anxiety 
12- month prevalence 14.4%) and previous IBD studies 
(depression prevalence 9.9%–20.5%, anxiety disorder 
prevalence 4.9%–36.5%).11 12 A recent pre- COVID19 
pandemic study found the prevalence of distress to be 
50% among Australian patients with IBD (K10 question-
naire).13 While we did not carry out a matched survey 
for healthy individuals, a recent study has looked at the 
mental health of people in Australia in the first month of 
the COVID-19 restrictions.14 The estimated prevalence of 
clinically significant symptoms of depression in that study 
was 27.6% and of clinically significant anxiety at 21%. 
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This is significantly higher than the reported rates in the 
Australian population in the pre COVID-19 era. Unfortu-
nately, this or other Australian studies, have not reported 
on the impact of the COVID-19 pandemic on people 
with pre- existing depression or anxiety. In our study half 
of all respondents had a diagnosis of anxiety or depres-
sion prior to the COVID-19 pandemic. Of those with 
no prior diagnosis, about a third were found to have at 
least moderate depression. At least moderate anxiety and 
stress were also found in a third of respondents without 
a prior diagnosis of anxiety or depression. This could be 
as a result of the COVID-19 pandemic, or, alternatively, 
a proportion of these individuals may have had undiag-
nosed anxiety or depression that predates the pandemic. 
Table 4 Predictors of at least moderate depression, anxiety and stress
Characteristic
Univariate analysis OR 
(95% CI) P value
Multivariate analysis 
OR (95% CI) P value
Age 1.94 (1.11 to 3.41) 0.021 0.96 (0.94 to 0.98) <0.001




Age at IBD diagnosis 0.98 (0.96 to 0.99) 0.009 0.297
Current steroid use 0.161
Immunomodulator (IM) and biological use
No IM or biologics Index 0.014 0.008
Combination therapy 0.92 (0.47 to 1.83) 0.819 0.69 (0.31 to 1.53) 0.357
IM monotherapy 0.33 (0.16 to 0.69) 0.003 0.26 (0.11 to 0.58) 0.001
Biologics monotherapy 0.76 (0.39 to 1.46) 0.408 0.76 (0.35 to 1.66) 0.495
IBD medication knowledge 0.71
IBD medication compliance 0.16
Symptom status:
No symptoms Index Index
Mild 2.08 (1.17 to 3.69) 0.012 1.74 (0.90 to 3.36) 0.099
Moderate 3.48 (1.69 to 7.17) 0.001 3.89 (1.69 to 8.93) 0.001
Severe 4.03 (1.77 to 9.17) 0.001 3.97 (1.52 to 10.4) 0.005
Usual caregiver
IBD clinic Index 0.439
General Gastroenterology clinic 3.28 (1.53 to 7.05) 0.002
Surgeon (Public & Private) 0.77 (0.12 to 4.84) 0.78
Private Gastroenterologist 2.12 (1.24 to 3.64) 0.006
General Physician 1.54 (0.59 to 4.04) 0.382
Lack of access to IBD nurse 1.65 (1.05 to 2.60) 0.031 1.81 (1.03 to 3.19) 0.04
Access to gastroenterologist phone- based review 0.211
Lack of advice from medical practitioner regarding 
reducing COVID-19 infection risk
1.74 (1.01 to 2.76) 0.018 1.99 (1.13 to 3.50) 0.017
Perceived increased susceptibility to COVID-19 
compared with general population:
Strongly agree Index Index
Agree 0.73 (0.42 to 1.27) 0.268 0.71 (0.38 to 1.35) 0.302
Neither agree nor disagree 0.32 (0.17 to 0.61) 0.001 0.22 (0.10 to 0.48) <0.001
Disagree 0.24 (0.82 to 0.72) 0.011 0.15 (0.04 to 0.54) 0.003
Strongly disagree 0.999 0.999
Exposure to COVID-19 information on the news 
and social media
0.88 –
95% CI is displayed for variables with statistically significant differences.
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It is also possible that there was a degree of response bias. 
People with pre- existing mental health issues might have 
been more likely to complete the questionnaire, leading 
to an overestimation of symptom prevalence.
Multivariate analysis of predictors of significant depres-
sion, anxiety and stress, can provide opportunities for 
interventions to combat the mental health burden of the 
COVID-19 pandemic among the IBD population. Access 
to an IBD nurse and advice from medical practitioner on 
reducing infection risk were two modifiable factors that 
may protect against significant depression, anxiety and 
stress. Investing healthcare resources to improve access 
to IBD nurses and ensure patients can readily access their 
treating doctor during the COVID-19 pandemic may, 
therefore, have a positive impact on the mental health 
of patients with IBD, among the other obvious benefits. 
Moderate to severe symptomatically active disease also 
predicted for significant depression, anxiety and stress 
during the COVID-19 pandemic, as has been found in 
prior studies.3 Immunomodulator use was associated with 
lower depression, anxiety and stress. This association 
remained significant even on multivariate analysis, hence 
this observation is not only due to reduction in symptoms 
or reduced use of corticosteroids. Their use to control 
symptoms may potentially raise less concerns to patients 
than steroids and biologics during the pandemic. This 
may also explain why biological monotherapy and combi-
nation therapy did not reach statistical significance. The 
mental well- being of patients also needs to be considered 
in choosing to follow blanket recommendations for cessa-
tion of immunomodulators and biologics among patients 
with IBD in areas experiencing high infection rates.15 
The latest European Crohn's and Colitis organisation 
(ECCO) guidelines take a more individualised approach 
and advise for continuation of medications among most 
uninfected patients with IBD.16
Patients with IBD have been found to have greater fears 
of COVID-19 infection than the general population.17 
Many believe themselves to have higher than average 
susceptibility to COVID-19. Preliminary studies indicate 
that overall patients with IBD are not more susceptible 
to COVID-19 than the general population, and this may 
only be true for a proportion of patients.18–20 Active IBD 
has been shown to be a risk factor for severe COVID-19 
infection.21 Glucocorticoids and 5- aminosalicylates have 
been implicated in severe cases of COVID-19 infection 
among patients with IBD, however, the same has not 
been clearly demonstrated for immunomodulators and 
biologics.22–24 A meta- analysis of studies found a lower 
incidence of COVID-19 infection among IBD popula-
tions, when compared with incidence reported in general 
population studies.25 This lower incidence may reflect 
higher precautions taken by patients with IBD on average 
compared with the general population. Nevertheless, the 
perception of increased susceptibility to COVID-19 was 
associated with significant depression, anxiety and stress 
in our study population. A survey among Italian patients 
with IBD found that half believed themselves to be 
more susceptible to severe COVID-19 infection, and this 
resulted in more absence from work.26 Reassurance and 
evidence- based advice from health providers may address 
this factor. Of interest, although some have found a 
negative association between COVID-19 news and social 
media exposure on mental well- being, this was not the 
case with our study.27
Technology can assist in ensuring patient with IBD 
follow- up while maintaining social distancing. In Italy, 
patients with IBD in the ‘red zone’ were followed up by 
physicians and psychiatrists using telehealth.28 Although 
not quantified, many patients reported anxiety and panic 
attacks, and the telehealth follow- up was beneficial.
Several factors may have impacted our results. Although 
efforts were made to advertise the study as widely as 
possible, a degree of selection bias is unavoidable: Indi-
viduals with IBD that spend more time on the internet 
and social media are potentially more likely to have been 
made aware of this study. Similarly, those with more free 
time may be more likely to complete the survey. Another 
limitation of the study is the relatively small sample size of 
352 respondents. IBD is estimated to affect around 89 000 
persons in Australia, which means our survey captured 
less than 1% of the affected population.29 Low partici-
pation rate could be secondary to the limited time the 
survey was available online. The survey was run for 3 weeks 
to capture responses during a period of maximum lock 
down restrictions. Also, online surveys are less accessible 
to people who lack computer proficiency and hence 
they would be under- represented in this study. NSW as a 
state was over- represented in proportion of responders. 
NSW did have the greatest proportion of COVID-19 cases 
compared with other states. The COVID-19 pandemic 
may hence have been of greater concern on average 
to patients living in NSW compared with other states, 
potentially making them more likely to take the time to 
complete the survey. As the survey was anonymous and 
patients were not approached directly, reminders could 
not be sent out to individuals to complete the survey.
As this is a cross- sectional study, we cannot accurately 
determine how much of the mental health burden 
observed within our IBD population is a direct effect of 
the COVID-19 pandemic. Nevertheless, the high rates 
of depression, anxiety and stress within our study popu-
lation has highlighted the need for broader studies to 
be carried out to confirm these findings.
The nature of the data and its analysis may also be a 
source of bias. Many of our survey questions use Likert 
scales. Inaccuracy is introduced in multivariate analysis 
due to an assumption of equidistance between responses, 
as would be the case with continuous scales.
To conclude, Australian patients with IBD appear 
to have high rates of mental health problems and the 
COVID-19 pandemic is a significant exacerbator. Inter-
ventions are needed to address this such as improving 
access to IBD nurses, physician advice and ongoing 
symptom management. Further studies to monitor rates 
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and to assess the effectiveness of various interventions are 
required.
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